Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Palisade Bio (PALI) Equity Average (2016 - 2025)

Historic Equity Average for Palisade Bio (PALI) over the last 15 years, with Q3 2025 value amounting to $2.9 million.

  • Palisade Bio's Equity Average fell 6477.62% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 6477.62%. This contributed to the annual value of $9.4 million for FY2024, which is 2096.08% down from last year.
  • As of Q3 2025, Palisade Bio's Equity Average stood at $2.9 million, which was down 6477.62% from $4.0 million recorded in Q2 2025.
  • Palisade Bio's 5-year Equity Average high stood at $14.9 million for Q3 2023, and its period low was -$18.3 million during Q1 2021.
  • For the 5-year period, Palisade Bio's Equity Average averaged around $5.5 million, with its median value being $7.7 million (2024).
  • Per our database at Business Quant, Palisade Bio's Equity Average plummeted by 163566.2% in 2021 and then skyrocketed by 40124.91% in 2022.
  • Quarter analysis of 5 years shows Palisade Bio's Equity Average stood at -$2.8 million in 2021, then surged by 550.92% to $12.5 million in 2022, then rose by 1.95% to $12.7 million in 2023, then tumbled by 44.48% to $7.0 million in 2024, then tumbled by 58.64% to $2.9 million in 2025.
  • Its Equity Average stands at $2.9 million for Q3 2025, versus $4.0 million for Q2 2025 and $6.4 million for Q1 2025.